Top

Osteoporosis International

Published in:

01-11-2013 | Original Article

Bone health and aldosterone excess

Authors: L. Ceccoli, V. Ronconi, L. Giovannini, M. Marcheggiani, F. Turchi, M. Boscaro, G. Giacchetti

Published in: Osteoporosis International | Issue 11/2013

Abstract

Summary

A picture of hyperparathyroidism secondary to increased urinary calcium excretion was found in 116 patients with primary aldosteronism (PA), compared with 110 essential hypertensives. After medical or surgical treatment in 40 PA patients, parathyroid hormone (PTH) levels were significantly reduced and bone mineral density (BMD) significantly increased at the lumbar spine, femoral neck, and total hip.

Introduction

Recent studies have shown that aldosterone induces urinary calcium excretion leading to a reduction of calcemia with consequent secondary hyperparathyroidism and BMD loss. In patients with PA, this picture of hyperparathyroidism is significantly improved by treatment with adrenal surgery or with mineralocorticoid receptor antagonists. On these premises, the aim of the present study was to evaluate calcium and phosphate metabolism parameters in PA patients, compared with patients with essential hypertension (EH) and the effect of treatment of aldosterone excess on bone health in PA patients.

Methods

We studied 226 patients: 116 with PA (46 with an aldosterone-producing adenoma and 70 with bilateral adrenal hyperplasia) and 110 patients with EH. In 40 patients with PA, we evaluated biochemical parameters and bone mass, using the dual-energy X-ray absorptiometry, at baseline and after a mean follow-up of 24 months from treatment.

Results

In PA patients, compared with EH, PTH levels and urinary calcium excretion significantly increased while serum calcium significantly decreased with comparable vitamin D levels. At follow-up in PA patients, PTH levels were significantly reduced compared with basal evaluation, despite similar vitamin D amounts. At follow-up, we observed a significant improvement of the Z-score at the lumbar spine, femoral neck, and at total hip sites.

Conclusions

Our results support previous data showing secondary hyperparathyroidism in PA patients, which is reversible after treatment. Moreover, this targeted treatment appears to be able to determine a significant improvement of BMD both at the spine and hip sites.

Stowasser M (2009) Update in primary aldosteronism. J Clin Endocrinol Metab 94(10):3623–3630PubMedCrossRef

Hagstrom E, Hellman P, Larsson TE, Ingelsson E, Berglund L, Sundström J, Melhus H, Held C, Lind L, Michaëlsson K, Arnlöv J (2009) Plasma parathyroid hormone and the risk of cardiovascular mortality in the community. Circulation 119(21):2765–2771PubMedCrossRef

Pilz S, Tomaschitz A, Drechsler C, Ritz E, Boehm BO, Grammer TB, März W (2010) Parathyroid hormone level is associated with mortality and cardiovascular events in patients undergoing coronary angiography. Eur Heart J 31(13):1591–1598PubMedCrossRef

Peter H, Law PH, Sun Y, Bhattacharya SK, Chhokar VS, Weber KT (2005) Diuretics and bone loss in rats with aldosteronism. J Am Coll Cardiol 46(1):142–146CrossRef

Chhokar VS, Sun Y, Bhattacharya SK, Ahokas RA, Myers LK, Xing Z, Smith RA, Gerling IC, Weber KT (2005) Hyperparathyroidism and the calcium paradox of aldosteronism. Circulation 111(7):871–878PubMedCrossRef

Pilz S, Kienreich K, Drechsler C, Ritz E, Fahrleitner-Pammer A, Gaksch M, Meinitzer A, März W, Pieber TR, Tomaschitz A (2012) Hyperparathyroidism in patients with primary aldosteronism: cross-sectional and interventional data from the GECOH study. J Clin Endocrinol Metab 97(1):E75–E79PubMedCrossRef

Rossi GP, Ragazzo F, Seccia TM et al (2012) Hyperparathyroidism can be useful in the identification of primary aldosteronism due to aldosterone-producing adenoma Aug ;60(2):431–6

Maniero C, Fassina A, Seccia TM, Toniato A, Iacobone M, Plebani M, De Caro R, Calò LA, Pessina AC, Rossi GP (2012) Mild hyperparathyroidism: a novel surgically correctable feature of primary aldosteronism. J Hypertens 30(2):390–395PubMedCrossRef

Salcuni AS, Palmieri S, Carnevale V, Morelli V, Battista C, Guarnieri V, Guglielmi G, Desina G, Eller-Vainicher C, Beck-Peccoz P, Scillitani A, Chiodini I (2012) Bone involvement in aldosteronism. J Bone Miner Res 27(10):2217–2222PubMedCrossRef

10.

Giacchetti G, Ronconi V, Lucarelli G, Boscaro M, Mantero F (2006) Analysis of screening and confirmatory tests in the diagnosis of primary aldosteronism: need for a standardized protocol. J Hypertens 24(4):737–745PubMedCrossRef

11.

Funder JW, Carey RM, Fardella C, Gomez-Sanchez CE, Mantero F, Stowasser M, Young WF Jr, Montori VM (2008) Case detection, diagnosis, and treatment of patients with primary aldosteronism: an Endocrine Society Clinical Practice Guideline. J Clin Endocrinol Metab 93(9):3266–3281PubMedCrossRef

12.

Monticone S, Satoh F, Giacchetti G, Viola A, Morimoto R, Kudo M, Iwakura Y, Ono Y, Turchi F, Paci E, Veglio F, Boscaro M, Rainey W, Ito S, Mulatero P (2012) Effect of adrenocorticotropic hormone stimulation during adrenal vein sampling in primary aldosteronism. Hypertension 59(4):840–846PubMedCrossRef

13.

Rossi GP, Sacchetto A, Chiesura-Corona M, De Toni R, Gallina M, Feltrin GP, Pessina AC (2001) Identification of the etiology of primary aldosteronism with adrenal vein sampling in patients with equivocal computed tomography and magnetic resonance findings: results in 104 consecutive cases. J Clin Endocrinol Metab 86:1083–1090PubMedCrossRef

14.

Pedrazzoni M, Girasole G, Bertoldo F, Bianchi G, Cepollaro C, Del Puente A, Giannini S, Gonnelli S, Maggio D, Marcocci C, Minisola S, Palummeri E, Rossini M, Sartori L, Sinigaglia L (2003) Definition of a population specific DXA reference standard in Italian women: the Densitometric Italian Normative Study (DINS). Osteoporos Int 14(12):978–982PubMedCrossRef

15.

Carnevale V, Pipino M, Antonacci M, Checchia C, D’Alessandro V, Errico M, Greco A, Varriale A (2005) Prevalence of hypercalcemia in hospitalised patients: effects of “correction” for serum albumin values. J Endocrinol Invest 28(5):RC15–RC17PubMed

16.

Kamalov G, Bhattacharya SK, Weber KT (2010) Congestive heart failure: where homeostasis begets dyshomeostasis. J Cardiovasc Pharmacol 56(3):320–328PubMedCrossRef

17.

Gupta M, Cheung CL, Hsu YH, Demissie S, Cupples LA, Kiel DP, Karasik D (2011) Identification of homogeneous genetic architecture of multiple genetically correlated traits by block clustering of genome-wide associations. J Bone Miner Res 26(6):1261–1271PubMedCrossRef

18.

Beavan S, Horner A, Bord S, Ireland D, Compston J (2001) Colocalization of glucocorticoid and mineralocorticoid receptors in human bone. J Bone Miner Res 16(8):1496–1504PubMedCrossRef

19.

Batista MC, Mendonça BB, Kater CE, Arnhold IJ, Rocha A, Nicolau W, Bloise W (1986) Spironolactone-reversible rickets associated with 11 beta-hydroxysteroid dehydrogenase deficiency syndrome. J Pediatr 109(6):989–993PubMedCrossRef

20.

Agarwal MK, Mirshahi F, Mirshahi M, Bracq S, Chentoufi J, Hott M, Jullienne A, Marie PJ (1996) Evidence for receptor-mediated mineralocorticoid action in rat osteoblastic cells. Am J Physiol 270:C1088–C1095PubMed

21.

Farquharson CA, Struthers AD (2000) Spironolactone increases nitric oxide bioactivity, improves endothelial vasodilator dysfunction, and suppresses vascular angiotensin I/angiotensin II conversion in patients with chronic heart failure. Circulation 101:594–597PubMedCrossRef

22.

Zhang YB, Zhong ZM, Hou G, Jiang H, Chen JT (2011) Involvement of oxidative stress in age-related bone loss. Surg Res 169(1):e37–e42CrossRef

23.

Maniero C, Fassina A, Guzzardo V, Lenzini L, Amadori G, Pelizzo MR, Gomez-Sanchez C, Rossi GP (2011) Primary hyperparathyroidism with concurrent primary aldosteronism. Hypertension 58(3):341–346PubMedCrossRef

Title: Bone health and aldosterone excess
Authors: L. Ceccoli
V. Ronconi
L. Giovannini
M. Marcheggiani
F. Turchi
M. Boscaro
G. Giacchetti
Publication date: 01-11-2013
Publisher: Springer London
Published in: Osteoporosis International / Issue 11/2013
Print ISSN: 0937-941X
Electronic ISSN: 1433-2965
DOI: https://doi.org/10.1007/s00198-013-2399-1

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Bone health and aldosterone excess

Abstract

Summary

Introduction

Methods

Results

Conclusions

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Summary

Introduction

Methods

Results

Conclusions

Please log in to get access to this content

Other articles of this Issue 11/2013

Erratum to: Correlation between 25-hydroxyvitamin D levels and latitude in Brazilian postmenopausal women: from the Arzoxifene Generations Trial

Pseudoarthrosis in atypical femoral fracture: case report

The effect of physical exercise on bone density in middle-aged and older men: A systematic review

Generation and validation of a normative, age-specific reference curve for lumbar spine trabecular bone score (TBS) in French women

Erratum to: A case of an atypical femoral fracture associated with bacterial biofilm—pathogen or bystander?

Greater intake of fruit and vegetables is associated with a lower risk of osteoporotic hip fractures in elderly Chinese: a 1:1 matched case–control study